Vaccines

Vaccines

Vaccine manufacturers from all over the world have been involved in a stalemate with governments regarding supply and demand. While governments are reluctant to ensure steady demand for vaccines unless the manufacturers can prove their ability to increase their supply, the latter are apprehensive about increasing production without a guarantee of sustained demand from the governments. Meanwhile, developing nations are increasingly demanding vaccines that are no longer included in the immunization schedules of developed countries. These vaccines will have to be provided at very low costs, which will not be feasible unless the demand can compensate for the low margins. Global vaccines market is estimated at USD10 billion in 2007; human vaccine valued at USD8.3 billion contributes major share ie 83% of the total market and rest 17% is occupied by animal vaccine valued at USD1.7 billion. The US is the leading market, accounting for more than 50% of the global vaccine market. Influenza vaccine is the fastest growing in the adult vaccine segment followed by Hepatitis vaccines.The vaccines market in India in 2006-07 was INR30.53 billion registering a 30.41% growth over the previous year. India’s huge population makes it among the world’s largest market for vaccines of all types. India faces a growing demand for new generation and ‘combination’ vaccines, such as DPT with Hepatitis B, Hepatitis A and Injectable polio vaccine, besides
several veterinary and poultry vaccines. Indian vaccines market is dominated by paediatric vaccine with 60% of market share. Combination vaccines are driving the growth of vaccine market in India. ‘Industry Insight - Vaccines’ report is prepared keeping in mind the current growth in
demand for vaccines in India.The report attempts to cover the industry with a perspective of global vaccines market, segments and its growth in demand.
o A market assessment of vaccines segment with reference to the market size and market trend is presented.
o Vaccines report presents the growth drivers such as increasing population, disease awareness etc.
o It presents the issues and challenges involved in vaccines with reference to vaccine funding, timely regulatory clearance.
o It provides information on the critical success factors such as pricing, government programmes etc
o 10 Major players have been profiled providing introduction, financial, operational details of the company.
o The report presents a brief outlook about the regulatory issues and also the regulatory aspects involved in vaccines segment.
o The report provides a future outlook of vaccines market.

EXECUTIVE SUMMARY 7 HIGHLIGHTS101. Introduction.12 2. Market overview 16 2.1 Global market overview 16 2.1.1 Introduction 16 2.1.2 Market scenario 16 2.1.2.1Market segmentation 17 2.1.2.2 Market trends 17 2.1.2.3 Major players 18 2.1.3 Major markets 26 2.1.3.1 USA 26 2.1.3.2 Europe 27 2.1.4 Outlook 27 2.2 Indian market overview 28 2.2.1 Introduction 28 2.2.2 Current Market scenario.29 2.2.2.2 Market size 30 2.2.2.1 Market segment 30 2.2.2.3 Market trends 35 2.2.3 Outlook 40 3 Growth drivers 41 3.1 Increasing Population in Developing Countries 41 3.3 Diseases prevention 42 3.4 Blockbuster Potential of New Vaccines 43 3.5 Disease Awareness 45 3.6 India - Future Hub for Paediatric Vaccine Manufacturing 45 4 Issues and challenges 46 4.1 Vaccine Funding 46 4.2 Lack of infrastructure for Trials & Manufactures 46 4.3 Dependence on government by domestic companies 47 4.4 Timely Regulatory Clearance 47 4.5 Vaccine Supply 48 5 Critical success factors 49 5.1 Pricing.49 5.2 Funding from Government & NGOs 50 5.3 Distribution network 50 5.4 Government immunisation programme 51 5.5 Storage Infrastructure 53 6. MAJOR PLAYERS 54 6.1. Serum Institute of India Ltd 55 6.2 Panacea Biotech Ltd.62 6.3 Venkateshwara Hatcheries Private Ltd 68 6.4 Indian Immunological Ltd 72 6.5 GlaxoSmithKline Pharmaceuticals Ltd. 77 6.6 Aventis Pharma Limited 83 6.7 Shantha Biotechnics 89 6.8. Eli Lilly India 95 6.9. Haffkine Bio Pharmaceutical Corporation Ltd (HBCL) 97 6.10. Intervet India 100 7. Regulatory Environment. 103 7.1 U.S.A 103 7.2 Europe 106 7.3 India 110 8. Future outlook.141 List of Tables Table 2.1: Global vaccine companies revenue Table 2.2: Key alliances of Sanofi-Aventis Table 2.3: R&D pipeline of Sanofi-Aventis Table2.4: Segmental revenue in Biopharma sector Table 2.5: Products segment in the vaccine market Table 2.6: Top ten vaccine players in India Table 2.7: Major vaccines Table 2.8: Vaccines launched in India Table 3.1: Combination of vaccines Table 3.2: New combination of vaccines Table 6.1: Top ten players in India biopharma sector Table 7.1: Some bio piracy patents based on indigenous knowledge of India List of Figures Figure 2.1: Geographical segments of vaccine markets Figure 2.2: Global vaccine market Figure 2.3 Sanofi-aventis vaccine segment Figure 2.4: Glaxo Smith Kline vaccine segment Figure 2.5: Novartis vaccine segment region wise Figure 2.6: Merck vaccine segment Figure 2.7: Segment wise biopharma sales contribution Figure 2.8: Segment wise biopharma sales contribution Figure 2.9: Indian vaccine market Figure 2.10: Segment wise contribution in the animal vaccine market Figure 2.11: Major players in Indian poultry vaccine market Figure 8.1: Indian biopharmaceutical market forecast Figure 8.2 Indian vaccine market forecast